#### Systematic druggable genome-wide Mendelian randomization identifies 1

#### therapeutic target genes for chronic periodontitis 2

- Zhongwei Cheng<sup>1#</sup>, Fang Wang<sup>1#</sup>, Meimei Ran<sup>3‡</sup>, Shenhu Liang<sup>2‡</sup>, Qinggao Song<sup>1\*</sup> 3
- 4
- 5 1 Department of Oral and Maxillofacial Surgery Affiliated Stomatological Hospital of Zunyi
- Medical University.Zunyi ,Guizhou,China. 6
- 7 2 School and Hospital of Stomatology, Zunyi Medical University, Zunyi ,Guizhou,China.
- 3 Information Technology Network Management Center, Zunyi Medical And Pharmaceutical 8
- 9 College, Zunyi, Guizhou, China.
- 10
- # These authors contributed equally to this work. 11
- 12 These authors also contributed equally to this work.
- \*Correspondence: Qinggao Song (814641639@gq.com) 13
- 14

#### 15 Abstract

Currently, the treatment of chronic periodontitis (CP) still has challenges. This study aimed to 16

- 17 identify novel drug targets for the treatment of chronic periodontitis in the druggable genome
- using the Mendelian randomization (MR) method. In this study, based on the list of 4479 drug gene 18
- 19 targets, overlapping genes were selected in blood expression Quantitative Trait Loci(eQTL), which
- 20 were then subjected to Two-Sample MR(TSMR) and validated Fusion Transcriptome-Wide
- Association Study(TWAS) with data from the Genome-Wide Association Study(GWAS) of CP to 21
- 22 confirm drug genes genetically associated with CP and tested for multiplicity of effects using
- 23 Summary-data-based Mendelian randomization(SMR) analysis and colocalisation. Finally,
- 24 Phenome-Wide association study(PheWAS) was executed on the identified drug targets.We
- 25 applied SMR,TSMR,Fusion TWAS,and a series of manners of co-localisation to assess the genetic
- 26 association between drugable targets and CP. In conclusion, Metalloproteinase 25(MMP25) was
- 27 considered the most promising drug target, in addition to which we maintained some confidence in
- 28 TNFRSF18,CDC25B,STK10 and ACVR2B.Finally,the PheWAS-MR results showed that the
- 29 possible side effects of applying MMP25 inhibitors were Otitis externa as well as some metabolic
- disorders, among others. In summary, we identified five potential CP drug targets using 30
- TSMR, Fusion TWAS, SMR, and co-localisation a series of methods, of which MMP25 passed all 31
- 32 the tests.Such discovery offered an academic basis for future CP drug development and reduce
- 33 drug development time and economic costs to some extent.
- Keywords:Chronic periodontitis,Genome-wide Mendelian randomisation,Target genes. 34
- 35

#### Introduction 36

- Periodontitis affects approximately 70-80% of adults and is the sixth most epidemic illness around 37
- the world [1], it causes severe inflammation in the tissues surrounding teeth, such as gums, 38
- alveolar bone and periodontal ligament, which, in addition to the tooth loss, bone loss, and 39
- 40 formation of periodontal pockets [2,3], is also closely associated with a number of systemic
- 41 illness, such as diabetes mellitus, cardiovascular disease, and chronic kidney disease [4-7]. The
- persistent progression of gingival recession in chronic periodontitis (CP) severely reduces the 42
- <sup>43</sup> patients' life quality and brings social health organisations a great challenge [1]. In fact, the

pathogenesis of chronic periodontitis is complex and multifactorial, and although microbial 44 45 infection of the periodontal biofilm is the main etiological factor, it is also largely related to a

combination of host autoimmune characteristics, environmental factors, and genetic 46

47 susceptibility[8-10], which makes it difficult to treat chronic periodontitis effectively.

48 Previous studies have shown that anti-cytokine therapy (inhibition of tumour necrosis factor, 49 interleukin-1 or interleukin-17 action) has demonstrated some efficacy in experimental models of periodontitis [11] and several clinical studies have evaluated antirheumatic drugs (anabolic acid, 50 51 etanercept and infliximab, among others) and NSAIDs as having a positive effect on periodontitis [12]. In addition, Amyndas Pharmaceuticals approved the development of new drugs (e.g. 52 improved analogues of the C3 inhibitor conistatin family, i.e. Cp40), which set the stage for the 53 progression of AMY-101 [13-15]. However, in host regulation therapies, there may be potential 54 safety problems involving biological targeting specific components of the immune response, 55 56 includes the infection risk increased, especially with the long-term use of NSAIDs, where the possibility of ill effects and unknown hazards is greater [9][16,17]. Therefore, there is a need to 57

58 continue to explore potential therapeutic gene targets for CP therapy.

59 Mendelian randomization (MR) has been used in various fields of medicine as an effective 60 method to speculate causality between two phenotypes by genetic variants as instrumental 61 variables (IVs) [18]. In addition MR analysis can be used to find new drug targets by 62 consolidating pooled data from illness genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) researchs [19]. In druggable genes' genomic regions, eQTLs was 63 found to represent characterising traits, as the level of gene expression could be viewed as a kind 64 of lifelong exposure [20]. So we conducted a scientific genome-wide MR study to search possible 65 targets for chronic periodontitis treatment. Firstly, we screened cis-eOTLs from blood eOTLs 66 67 through information of drug genes list. Using GWAS data of chronic periodontitis, two-sample MR analysis was taked to identify genes highly related to chronic periodontitis. Then we 68 performed SMR analysis, co-localisation analysis, and TWAS analysis to prove the robustness of 69 70 the MR results. Phenome-wide association study (PheWAS) was then performed on the identified drug targets. 71

72

#### 73 Materials and methods

Our study design process is shown in Fig1. The following is a detailed description of the methods 74 75 and materials used in this study.

76

77 Figure 1.Flowchart of the design of this study. MAF: Minor allele frequency; eQTL: Expression quantitative 78 trait loci; SMR:Summary-data-based Mendelian randomization;GWAS: Genome-wide association Studies;

79 TWAS:Transcriptome-wide association analysis; PheWAS: Phenome-wide association study.

#### 80 Source of druggable gene targets

In order to be able to provide a comprehensive and credible list of druggable gene targets for 81

subsequent studies, we selected a list of 4,479 druggable genes (20,300 protein-coding genes 82

annotated in Ensembl v.73) consolidated by Finan C, et al [21], which has 31.9% (1,427/4479) of 83

84 genes with approved or clinical-stage drug targets, 15.2% (689/4479) of the genes are similar to

85 approved drug targets and 52.9% (2370/4479) encode proteins that are remotely similar to

approved drug targets, which are widely used in many studies today [22]. Information of 86

druggable genes on the list comes from the original article's publicly available supplementary 87

#### material. 88

#### 89 Chronic periodontitis GWAS data and eOTL dataset GWAS data sources

- 90 The raw eQTL public data downloaded from the official eQTLGen (https://eqtlgen.org/) website
- 91 [23], which summarises cis-eQTL for 16,987 genes (318,614 blood samples from healthy
- 92 individuals of European descent), and the current study only included samples from this raw
- 93 dataset with false discovery rate (FDR) < 0.05 in this original dataset.
- 94 Chronic periodontitis GWAS data were obtained from the Finnish database version R11 95 (updated 24 June 2024), which includes 5,364 cases and 288,472 controls of European origin, in
- the Finnish database under the category 'Diseases of the digestive system'. The phenotype 96
- 97 'Chronic periodontitis' was searched in the Finnish database under the category 'Diseases of the
- digestive system' and was downloaded with reference to ICD-10:K05.30 and K05.31 or 98
- 99 ICD-9/ICD-8:5234 for inclusion criteria [24]. And various genetic principal components were
- 100 adjusted (age, sex, and 20 others). In this study, data were downloaded from public databases or
- official websites, all original studies involved have received ethical approval, and the ethical 101
- 102 committee approval was not required for this particular aspect of the study.

#### Screening of instrumental variable 103

- 104 In this study, SNPs with overlapping druggable genes transcriptional start site (TSS)  $\pm 100$ KB
- 105 were extracted from the eQTL dataset as instrumental variables based on the list of druggable
- genes. Additionally three key assumptions had to be met for MR causal inference. i):IVs must 106
- 107 have evidence of characterised exposure, therefore a genome-wide significance threshold  $(5 \times 10^{-8})$
- and the linkage disequilibrium (LD) threshold  $R^{2}<0.1$  were set in this study (based on 1,000 108
- Genomes Project European population) to screen eligible IVs and excluded weak instrumental 109
- variables with F-statistics less than 10 [25]; ii): IVs must not be associated with confounders of 110
- 111 chronic periodontitis; and iii) IVs must pass the test of horizontal pleiotropy [26-27].

#### Statistical analysis 112

- For MR inference methods there are several to pick from; when the number of IVs characterising 113
- 114 the exposure is 1, the Wald ratio is chosen as the appropriate method for causal inference [28];
- when the number of IVs is greater than or equal to 2, the IVW method with strong statistical 115
- 116 validity is chosen, the OR calculation relies on the Wald ratio method [29] and the delta method
- 117 assesses the corresponding 95% confidence interval. In addition to this, we coordinated the
- exposure and outcome data according to the effect and non-effect alleles of each SNP. SNPs with 118
- 119 allelic mismatches were excluded to ensure data integrity. Finally, FDR was used to adjust for type
- 120 1 errors from multiple hypothesis testing (PFDR<0.05) [30].

#### 121 Multiple validity testing

- Since the IVs used in this MR study originated from single-gene regions, multiple gene region 122 123 pleiotropy detection methods (e.g., MR-Egger intercept) were no longer applicable, and we used
- 124 summary-data-based Mendelian randomisation (SMR) and Bayesian co-localisation to complete
- the single-gene region horizontal pleiotropy association detection, where SMR was combined with 125
- Heterogeneity In Dependence Instrumental Variables(HEIDI) to detect heterogeneity in the results 126
- [31]. In addition co-localisation of five mutually exclusive models corresponding to five posterior 127
- 128 probabilities [32]: PPH0-PPH4. In this study, co-localisation analyses were performed using SNPs
- 129 within  $\pm 100$  kb of the TSS of each gene in the eQTL and concluded that the genetic association
- between the expression level of the gene and the risk of chronic periodontitis was supported by the 130
- colocation when PPH4  $\geq$  0.6. 131

#### 132 TWAS Validation

- 133FUSION Transcriptome-Wide Association Study (TWAS) analyses are used to predict and test the
- correlation between gene expression and specific diseases or phenotypes by combining aggregated
- GWAS statistics with gene expression data, which can be used to predict and test the correlation
- between gene expression and specific diseases or phenotypes by identifying genes that are
- 137 significantly correlated with complex traits in individuals who do not have direct measurements of
- their expression levels, to provide a more comprehensive understanding of the genetic
- mechanisms of disease and guide future drug development and therapeutic strategies [33-34].
- 140 Download the code on Git-hub, containing the relevant code for mapping and making weight files
- 141 (https://github.com/gusevlab/fusion\_twas). top1, blup, lasso, enet, and bslmm are the five
- 142 prediction models used by FUSION, and we applied FUSION to correlate CP's genetic effects
- 143 with eQTL weights to calculate the linear product of Z-values of SNPs and eQTL weights for
- 144 TWAS analysis.

### 145 Phenome-wide association study

- 146 In order to assess the potential side effects of the identified drug targets, we performed
- 147 PheWAS-MR (https://www.leelabsg.org/resources) on selected phenotype-wide GWAS data (779
- 148 in total) from UK Biobank. The original database was adjusted for sample case-control imbalance
- 149 with cryptic relatedness using the Scalable and Accurate Implementation of Generalised mixed
- 150 model (SAIGE) (V.0.29) method to account for unbalanced of the case-control ratio [35]. In
- addition to this, the IVs screening strategy was harmonised with the above and the IVW method
- 152 was used as the primary method, with MR Egger, Weighted median and Weighted mode as the
- secondary methods for PheWAS-MR.Finally the FDR (BH) was used to correct for the multiple
   test results, and a PFDR < 0.05 was considered as the threshold of significance.</li>
- 155

## 156 **Results**

Selected according to the set screening criteria, this study extracted 2288 genes from the eQTL
dataset, corresponding to 27,496 IVs, (F-statistics ranging from 29.7-3450.7), and detailed
information of the IVs is shown in Additional Table 1.

160 This study ultimately investigated the genetic association of 2288 potential drug genes with 161 CP using MR (Additional Table 2), and after FDR correction, 13 genes were found to be genetically associated with CP (Fig. 2A and Fig. 2B), including matrix metallopeptidase 25 162 (MMP25) [odds ratio (OR)=1.13, 95% CI: 1.07-1.19,  $P = 1.45 \times 10^{-5}$ ], proteasome 20S subunit 163 alpha 4 (PSMA4) (OR = 1.39, 95% CI: 1.19-1.62,  $P = 2.74 \times 10^{-5}$ ) and muscleblind like splicing 164 regulator 1 (MBNL1) (OR=1.17, 95% CI: 1.08-1.26, P =  $3.70 \times 10^{-5}$ ) and seven other drug gene 165 expression levels were positively correlated with CP, whereas the expression levels of TNF 166 167 receptor superfamily member 18 (TNFRSF18) (OR=0.81, 95% CI. 0.73-0.89,  $P = 2.01 \times 10^{-5}$ ), serine/threonine kinase 10 (STK10) (OR = 0.78, 95% CI:  $0.69-0.89, P = 1.02 \times 10^{-4}$ ) and activin A 168 receptor type 2B (ACVR2B) (OR = 0.85, 95% CI: 0.79-0.93, P =  $1.21 \times 10^{-4}$ ) and eight other 169 drug gene expression levels were negatively correlated with CP. 170

- 171
- 172 Figure 2.Mendelian randomisation results of druggable genes with CP. A:Volcano plot of MR results. The
- size of the dots represents the size of PVE, and the purple dotted line indicates the threshold after FDR<0.05
- 174 correction.PVE: proportion of variance explained; PVE=sum((beta.exposure^2)/(beta.exposure^2 +
- samplesize.exposure \*se.exposure^2). B: Forest plot of MR results.

176	Multiplicity testing showed that only MMP25 was supported by SMR&HEIDI results and
177	co-localisation results, and passed the validated Fusion TWAS test. In addition, TNFRSF18, cell
178	division cycle 25B (CDC25B), STK10, and ACVR2B passed the SMR&HEIDI and validated
179	Fusion TWAS tests, but were not supported by co-localisation results (see Table 1 for detailed
180	results). Unfortunately, PSMA4 and ADAM10 only passed the validated Fusion TWAS test.
181	Then, based on the MR, SMR&HEIDI, co-localisation and validated Fusion TWAS test
182	results, we assigned endorsement grades to CP-associated pharmacogenes, among which we
183	maintained the highest confidence in MMP25, as the MR, SMR&HEIDI, co-localisation, and
184	validated Fusion TWAS test results all provided sufficient evidence of genetic linkage with CP
185	genetic association. We also maintained some confidence in TNFRSF18, CDC25B, STK10, and
186	ACVR2B as they passed MR, SMR&HEIDI, and validated Fusion TWAS test results, and just
187	failed co-localisation, which may be due to the low number of risk loci in the raw GWAS data for
188	CP. We had lower confidence in eight drug genes such as PSMA4, ADAM10 and NKTR.
189	Finally, since drugs usually act via blood circulation, we used PheWAS-MR to evaluate the
190	potential side effects of MMP25 as a drug target (Fig. 3). IVW results showed (FDR<0.05),
191	MMP25 was associated with 19 phenotypes (Additional Table 3), where MMP25 was the
192	Premature beats (OR=1.472 (OR=1.472, P=3.77×10 <sup>-6</sup> ), Dizziness and giddiness (OR=1.74,
193	P=6.97×10 <sup>-6</sup> ) and Type 2 diabetes with neurological manifestations (OR=1.39, P=9.91×10 <sup>-6</sup> ) were
194	13 phenotypic risk Factors. In contrast, MMP25 was a risk factor for Otitis externa (OR=0.717,
195	P=2.42×10-5), Other disorders of metabolism (OR=0.834, P=1.41×10 <sup>-4</sup> ) and Cellulitis and abscess
196	of trunk (OR=0.733, P = $2.68 \times 10^{-4}$ ) and other protective factors for six phenotypes.
197	The main statistical analysis was performed in R (version 4.3.3). Using the "coloc" software
198	package (version 5.2.1) for Bayesian colocation analysis, Two-sample MR analysis was conducted

199 with "MendelianRandomization" (version 0.6.6). SMR analysis from

200 https://yanglab.westlake.edu.cn/software/smr/#Download. TWAS analysis code from

- https://github.com/DelinLi/TWAS. 201
- 202 203

#### Table 1. Results of colocalization, SMR and TWAS analysis.

Cono	IVW_pval (FDR)	SMR_pval	HEIDI_pval	TWAS_pval	Co-localization
Gene					analysis
MMP25	0.019	0.002	0.731	7.71×10 <sup>-5</sup>	0.627
TNFRSF18	0.019	0.046	0.855	0.018	0.039
PSMA4	0.019	2.88×10-3	0.040	0.002	NA
MBNL1	0.019	0.034	0.545	NA	NA
CDC25B	0.019	0.036	0.502	0.011	0.022
BLK	0.024	0.309	0.102	0.325	NA
ALPL	0.026	0.027	0.086	NA	NA
ADAM10	0.026	0.141	0.709	0.035	NA
STK10	0.026	0.038	0.774	0.015	0.091
ACVR2B	0.028	0.034	0.195	0.032	0.07
NKTR	0.038	0.006	0.237	0.496	NA
KLHL3	0.038	0.208	0.987	NA	NA
GSTA4	0.038	0.002	0.648	NA	NA

204

Note:IVW, inverse variance weighted; SMR, Summary-data-based Mendelian randomization; HEIDI, Heterogeneity

205 In Dependence Instrumental Variables; TWAS, Transcriptome-Wide Association Study.

### 207 Discussion

206

This study used TSMR, Fusion TWAS, SMR, and co-localisation a range of methods to assess the
genetic association between druggable targets and CP. In conclusion, MMP25 passed all the tests
and therefore we maintain maximum confidence in it, in addition to TNFRSF18, CDC25B,
STK10 and ACVR2B. Finally, we investigated the potential side effects of MMP25 as a target

212 using PheWAS-MR.

MMP25 is an enzyme belonging to the MMP family.MMP participates in many 213 physiological processes and is a group of highly conserved endopeptidases [36-37]. Numerous 214 researches have indicated that the MMP family was vital in driving inflammation in periodontitis, 215 216 promoting periodontal tissue destruction through degradation and remodelling of extracellular 217 matrix components. Some in vitro experiments verified that the pathogenic bacterium causing CP (Fusarium nucleatum) promotes further inflammation in periodontal tissues, including alveolar 218 219 bone resorption and cellular matrix degradation, by stimulating macrophages to increase the 220 secretion of MMP9 [38]. It has been demonstrated that there may be a positive feedback loop 221 between MMP13 and MMP9, which together promote periodontal tissue inflammation and bone 222 loss [39]. Initially, it was found that MMP25 was specifically expressed in peripheral blood leukocytes and upregulated in mouse models of cancer and infection, and the close relationship 223 224 with periodontitis has been repeatedly demonstrated, for example, a randomised controlled trial 225 found that MMP25 levels in gingival sulcus fluid of patients with chronic periodontitis were higher than in healthy controls [40]. Another basic study found that levels of MMP25 in 226 periodontal tissues of chronic periodontitis increased. In conclusion, MMP25 is closely related to 227 228 chronic periodontitis, which is consistent with the conclusions reached in the current study [41].

229

### 230

### Figure 3.Results of MR studies of the full phenotypic range of MMP25.

TNFRSF18 is also referred to as Glucocorticoid-Induced TNFR-Related protein (GITR),
which has been linked to immune system homeostasis and inflammatory disease development.
Currently, although there are no direct studies on TNFRSF18 and CP, it has been reported that a
TNFRSF member, TNFSF14, was important in promoting the CXCL10 secretion and CXCL11
from human gingival fibroblasts, the infiltration of Th1 cells into foci of inflammatory illness can
be promoted, and was a prospective target for periodontitis treatment.

STK10 gene belongs to Ste20 family and encodes a serine/threonine protein kinase. The
protein binds to and phosphorylates polo-like kinase 1, its kinase-dead overexpression disturbs
cell cycle progression [42-43]; CDC25B belongs to phosphatases CDC25 family, and is necessary
for cells to enter mitosis [44]; ACVR2B acts as a signalling mediator with the ability to transmit
activin signals that regulate many pathological and physiological processes [45-46]. STK10,
CDC25B and ACVR2B have been little studied in CP, so further experiments are needed to verify
their association with CP.

In this study, we used many effective methods to improve the robustness of the MR study; firstly: the included instrumental variables all have F-statistics greater than 10, so they have the ability to characterise the drug genes; secondly, in order to unify the genomic co-ordinates, we localised the current MR study using SNPs to the human genome HG19/GRCh37; thirdly, we used Fusion TWAS to enhance the association between the drug association between genes and

CP; fourth, all GWAS data were from European ethnicity to reduce genetic confounding due to
ethnic differences; fifth, we selected only SNPs within the cis-eqtl region and used SMR and
co-localisation to avoid horizontal pleiotropy.

There are still limitations in this study. First, although MR verified the causal relationship 252 253 between drug gene targets and CP genetically via the IV method, the MR approach assumes a 254 linear relationship between CP and drug gene expression levels. Therefore, MR results should be 255 viewed with caution in case of nonlinear correlation between outcome and exposure. Secondly, 256 the GWAS data of the current study on the association between drug genes and CP were obtained from people of European descent. Therefore, the MR results need to be further investigated and 257 validated when extended to other ethnic groups to ensure wider applicability. Thirdly, this study 258 259 only concentrated on the causality between the pharmacogenetic cis-eOTL and CP, and lacked the 260 study of trans-eQTL. Finally, the results of this study need to be supported by clinical data, which is also the direction of our future efforts.

261 is also262

## 263 **Conclusion**

- Five potential CP drug targets were identified in this study using TSMR, Fusion TWAS, SMR,
- and a series of co-localisation methods, of which MMP25 passed all the tests, so we maintain the
- 266 utmost confidence in it. The findings provide a rationale for future CP drug development and
- reduce the cost of drug development to some extent.
- 268

## 269 Supporting information

- 270 S1 Fig.Flowchart of the design of this study.
- 271 S2 Fig.Mendelian randomisation results of druggable genes with CP.
- 272 S3 Fig.Results of MR studies of the full phenotypic range of MMP25.
- 273 S1 Table. Details of extracted instrumental variables.
- 274 S2 Table.MR results.
- 275 S3 Table.PheWAS-MR results.
- 276 S1 Checklist.STROBE-MR-checklist.
- 277

282

## 278 Acknowledgments

- 279 This study would like to thank the official eQTLGen (https://eqtlgen.org/) website and the Finnish
- 280 database version R11 (https://www.finngen.fi/fi) and public catalog GWAS data provided.Thanks
- to all authors for their contributions.

## 283 Author Contributions

- 284 Data curation: Zhong-wei Cheng, Fang Wang, Shen-hu Liang.
- 285 Formal analysis: Zhong-wei Cheng, Fang Wang, Qing-gao Song.
- 286 **Project administration:**Qing-gao Song.
- 287 Software:Mei-mei Ran.
- 288 Supervision:Shen-hu Liang.
- 289 Writing original draft:Zhong-wei Cheng.
- 290

## 291 **Funding information**

292 This research was supported by grands from the Zunyi United Fund: Innovative Team in Oral and

- 293 Maxillofacial Plastic Surgery (Code: Zunyi Science Cooperation HZ No. (2020) 294) and the
- 294 Zunyi Science and Technology Programme Funded Project (Nos. Zunyi Joint Fund,
- HZ2023-464). The funders had no role in study design, data colection and analysis, decision to

296 publish, or preparation of themanuscript.

297

## 298 Conflicts of Interest statement

299 The authors declared no potential conflicts of interest with respect to the research, authorship,

- 300 and/or publication of this article.
- 301

## 302 Data availability statement

All data included in this study are available upon request through contact with the correspondingauthor.

305

## 306 Ethics statement

In this study, data were downloaded from public databases or official websites, all original studiesinvolved have received ethical approval.

309

## 310 **References**

- [1] Eke PI, Thornton-Evans GO, Wei L, Borgnakke WS, Dye BA. (2018).Genco RJ.
  Periodontitis in US Adults: National Health and Nutrition Examination Survey 2009-2014. Journal
  of the American Dental Association, 149(7):576-588.e6. doi: 10.1016/j.adaj.2018.04.023.
- 314 [2] Tonetti MS, Jepsen S, Jin L, Otomo-Corgel J.(2017) Impact of the global burden of
  315 periodontal diseases on health, nutrition and wellbeing of mankind: A call for global action.
  316 Journal of Clinical Periodontology, 44(5):456-462. doi: 10.1111/jcpe.12732.
- 317 [3] Smith MM, Knight ET, Al-Harthi L, Leichter JW.(2017) Chronic periodontitis and implant
  318 dentistry. Periodontol 2000, 74(1):63-73. doi: 10.1111/prd.12190.
- [4] Parsegian K, Randall D, Curtis M, Ioannidou E.(2022) Association between periodontitis and
  chronic kidney disease. Periodontol 2000,89(1):114-124. doi: 10.1111/prd.12431.
- [5] Kavarthapu A, Gurumoorthy K.(2021) Linking chronic periodontitis and oral cancer: A
  review. Oral Oncology, 121:105375. doi: 10.1016/j.oraloncology.2021.105375.
- [6] Li S, Li H, Kong H, Wu SY, Cheng CK, Xu J.(2023) Endogenous and microbial biomarkers
  for periodontitis and type 2 diabetes mellitus. Front Endocrinol (Lausanne). 14:1292596. doi:
  10.3389/fendo.2023.1292596.
- 326 [7] Gao Chenyi., Iles Mark., Larvin Harriet., Bishop David Timothy., Bunce David., Ide Mark.,
- Sun Fanyiwen., Pavitt Susan., Wu Jianhua., Kang Jing. Genome-wide association studies on
  periodontitis: A systematic review. PLoS One,2024 September 6;19(9):1-23.
  doi:10.1371/journal.pone.0306983.
- [8] Radaic A, Kapila YL.(2021) The oralome and its dysbiosis: New insights into oral
  microbiome-host interactions. Computational and Structural Biotechnology Journal,19:1335-1360.
  doi: 10.1016/j.csbj.2021.02.010.
- [9] Hajishengallis G, Chavakis T, Lambris JD.(2020) Current understanding of periodontal
  disease pathogenesis and targets for host-modulation therapy. Periodontol 2000,84(1):14-34. doi:
  10.1111/prd.12331.
- 336 [10] Ana G, Sánchez-Medrano, Rita E, Martinez-Martinez, Ruth, Soria-Guerra, Diana,

Portales-Perez, Horacio, Bach, Fidel, Martinez-Gutierrez. A systematic review of the protein 337 composition of whole saliva in subjects with healthy periodontium compared with chronic 338 periodontitis. PLoS One, 2023 May, 18(5):1-12. doi:10.1371/journal.pone.0286079. 339

[11] Di Paola R, Mazzon E, Muià C, Crisafulli C, Terrana D, Greco S, Britti D, Santori D, Oteri 340 341 G, Cordasco G, Cuzzocrea S.(2007) Effects of etanercept, a tumour necrosis factor-alpha 342 antagonist, in an experimental model of periodontitis in rats. British Journal of Pharmacology, 150(3):286-97. doi: 10.1038/sj.bjp.0706979. 343

[12] Eskan MA, Jotwani R, Abe T, Chmelar J, Lim JH, Liang S, Ciero PA, Krauss JL, Li F, 344

Rauner M, Hofbauer LC, Choi EY, Chung KJ, Hashim A, Curtis MA, Chavakis T, Haiishengallis 345 G.(2012) The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. 346 Nature Immunology, 13(5):465-73. doi: 10.1038/ni.2260. 347

[13] Mastellos DC. D. Hajishengallis E. 348 Ricklin Hajishengallis G. Lambris 349 JD.(2016).Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Molecular Oral Microbiology, 31(1):3-17. doi: 10.1111/omi.12129 350

[14] Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello 351

RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, 352

353 Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD.(2018) 354 Safety profile after prolonged C3 inhibition. Clinical Immunology, 197:96-106. doi: 10.1016/j.clim.2018.09.004. 355

[15] Ricklin D, Mastellos DC, Reis ES, Lambris JD.(2018) The renaissance of complement 356 therapeutics. Nature Reviews Nephrology, 14(1):26-47. doi: 10.1038/nrneph.2017.156. 357

[16] Minaldi E, Cahill K.(2023) Recent Updates in Understanding NSAID Hypersensitivity. Curr 358 Allergy Asthma Rep.23(3):181-188. doi: 10.1007/s11882-023-01064-3. 359

360 [17] Szeto CC, Sugano K, Wang JG, Fujimoto K, Whittle S, Modi GK, Chen CH, Park JB, Tam LS, Vareesangthip K, Tsoi KKF, Chan FKL.(2020) Non-steroidal anti-inflammatory drug 361 (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal 362 APAGE/APLAR/APSDE/APSH/APSN/PoA 363 comorbidities: joint recommendations.Gut, 69(4):617-629. doi: 10.1136/gutinl-2019-319300. 364

365 [18] Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, Timpson NJ, Higgins JPT, Dimou N, Langenberg C, Loder EW, Golub RM, Egger M, Davey 366 Smith G, Richards JB.(2021) Strengthening the reporting of observational studies in epidemiology 367 using mendelian randomisation (STROBE-MR): explanation and elaboration. British Medical 368 Journal, 375:n2233. doi: 10.1136/bmj.n2233. 369

370 [19] Yu X, Liu S. Identifying potential drug targets for myocardial infarction through Mendelian randomization. PLoS One. 2024 Dec 23;19(12):e0313770. doi: 10.1371/journal.pone.0313770. 371

[20] Qi T, Song L, Guo Y, Chen C, Yang J.(2024) From genetic associations to genes: methods, 372 373 applications, and challenges. Trends in Genetics, 40(8):642-667. doi: 10.1016/j.tig.2024.04.008.

[21] Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, Galver L, Kelley R, 374

Karlsson A, Santos R, Overington JP, Hingorani AD, Casas JP.(2017) The druggable genome and 375

support for target identification and validation in drug development. Science Translational 376 377 Medicine, 9(383):eaag1166. doi: 10.1126/scitranslmed.aag1166.

378 [22] Zhang C, He Y, Liu L.(2024) Identifying therapeutic target genes for migraine by systematic

druggable genome-wide Mendelian randomization. The Journal of Headache and Pain. 2024 Jun 379

12;25(1):100. doi: 10.1186/s10194-024-01805-3. 380

[23] Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al.(2021) Large-scale 381 cis- and trans-eOTL analyses identify thousands of genetic loci and polygenic scores that regulate 382

blood gene expression. Nature Genetics, 53(9):1300-1310. doi: 10.1038/s41588-021-00913-z. 383

- [24] Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al.(2023) 384 385 FinnGen provides genetic insights from a well-phenotyped isolated population. Nature, 386 613(7944):508-518. doi: 10.1038/s41586-022-05473-8.
- [25] 1000 Genomes Project Consortium; Auton A, Brooks LD, Durbin RM, Garrison EP, Kang 387
- HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR.(2015) A global reference 388 for human genetic variation. Nature, 526(7571):68-74. doi: 10.1038/nature15393. 389
- [26] Greco M FD, Minelli C, Sheehan NA, Thompson JR.(2015) Detecting pleiotropy in 390 Mendelian randomisation studies with summary data and a continuous outcome. Statistics in 391 Medicine, 34(21): 2926-40. doi: 10.1002/sim.6522. 392
- 393 [27] Bowden J, Holmes MV.(2019) Meta-analysis and Mendelian randomization: A review. Res Synth Methods, 10(4):486-496. doi: 10.1002/jrsm.1346. 394
- 395 [28] Gudicha DW, Schmittmann VD, Vermunt JK.(2017) Statistical power of likelihood ratio and Wald tests in latent class models with covariates. Behav Res Methods, 49(5):1824-1837. doi: 396 397 10.3758/s13428-016-0825-y.
- 398 [29] Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP,
- Kutalik Z, Holmes MV, Minelli C, Morrison JV, Pan W, Relton CL, Theodoratou E.(2023) 399 400 Guidelines for performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Research, 4:186. doi: 10.12688/wellcomeopenres.15555.3. 401
- [30] Glickman ME, Rao SR, Schultz MR.(2014) False discovery rate control is a recommended 402 403 alternative to Bonferroni-type adjustments in health studies. Journal of Clinical Epidemiology, 404 67(8):850-7. doi: 10.1016/j.jclinepi.2014.03.012.
- [31] Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, Montgomery GW, Goddard 405
- ME, Wray NR, Visscher PM, Yang J.(2016) Integration of summary data from GWAS and eQTL 406 407 studies predicts complex trait gene targets. Nature Genetics. 2016 May;48(5):481-7. doi: 10.1038/ng.3538. 408
- [32] Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, Plagnol V. 409
- 410 (2014)Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genetics, 10(5):e1004383. doi: 10.1371/journal.pgen.1004383. 411
- [33] Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, Jansen R, de Geus EJ, Boomsma 412
- 413 DI, Wright FA, Sullivan PF, Nikkola E, Alvarez M, Civelek M, Lusis AJ, Lehtimäki T, Raitoharju
- 414 E, Kähönen M, Seppälä I, Raitakari OT, Kuusisto J, Laakso M, Price AL, Pajukanta P, Pasaniuc
- B.(2016) Integrative approaches for large-scale transcriptome-wide association studies. Nature 415
- 416 Genetics, 48(3):245-52. doi: 10.1038/ng.3506.
- 417 [34] Liu L, Yan R, Guo P, Ji J, Gong W, Xue F, Yuan Z, Zhou X.(2024) Conditional transcriptome-wide association study for fine-mapping candidate causal genes. Nature 418 Genetics, 56(2): 348-356. doi: 10.1038/s41588-023-01645-y. 419
- [35] Zhou W, Bi W, Zhao Z, Dey KK, Jagadeesh KA, Karczewski KJ, Daly MJ, Neale BM, Lee 420
- S.(2022) SAIGE-GENE+ improves the efficiency and accuracy of set-based rare variant 421 422 association tests. Nature Genetics, 54(10):1466-1469. doi: 10.1038/s41588-022-01178-w.
- [36] Chen J, Qin S, Liu S, Zhong K, Jing Y, Wu X, Peng F, Li D, Peng C.(2023) Targeting matrix 423
- 424 metalloproteases in diabetic wound healing. Frontiers in Immunology, 14:1089001. doi:

#### 425 10.3389/fimmu.2023.1089001.

- [37] Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC. Classical macrophage 426 activation up-regulates several matrix metalloproteinases through mitogen activated protein 427
- kinases and nuclear factor-κB. PLoS One. 2012;7(8):e42507. doi: 10.1371/journal.pone.0042507. 428
- 429 [38] Grenier D, Grignon L.(2006) Response of human macrophage-like cells to stimulation by
- 430 Fusobacterium nucleatum ssp. nucleatum lipopolysaccharide. Oral Microbiology Immunology,
- 21(3):190-6. doi: 10.1111/j.1399-302X.2006.00278.x. 431
- [39] Hernández M, Dutzan N, García-Sesnich J, Abusleme L, Dezerega A, Silva N, González FE, 432
- Vernal R. Sorsa T. Gamonal J.(2011) Host-pathogen interactions in progressive chronic 433
- periodontitis. Journal of Dental Research, 90(10):1164-70. doi: 10.1177/0022034511401405. 434
- [40] Emingil G, Kuula H, Sorsa T, Atilla G.(2006) Gingival crevicular fluid matrix 435 metalloproteinase-25 and -26 levels in periodontal disease. Journal of Periodontology, 436 437 77(4):664-71. doi: 10.1902/jop.2006.050288.
- [41] Kuula H, Salo T, Pirilä E, Hagström J, Luomanen M, Gutierrez-Fernandez A, Romanos GE, 438
- Sorsa T.(2008) Human beta-defensin-1 and -2 and matrix metalloproteinase-25 and -26 expression 439 in chronic and aggressive periodontitis and in peri-implantitis. Archives of Oral Biology, 440 441 53(2):175-86. doi: 10.1016/j.archoralbio.2007.09.010.
- 442 [42] Leroy C, Belkina NV, Long T, Deruy E, Dissous C, Shaw S, Tulasne D.(2016) Caspase Cleavages of the Lymphocyte-oriented Kinase Prevent Ezrin, Radixin, and Moesin 443 444 Phosphorylation during Apoptosis. Journal of Biological Chemistry, 291(19):10148-61. doi: 445 10.1074/jbc.M116.721365.
- [43] Hong H, Xu G, Bao G, Zhang J, Chen C, Chen J, Wu C, Jiang J, Huang J, Huang H, Cui 446 Z.(2024) VIRMA promotes neuron apoptosis via inducing m6A methylation of STK10 in spinal 447 448 cord injury animal models. CNS Neuroscience & Therapeutics, 30(3):e14453. doi: 10.1111/cns.14453. 449
- [44] Timofeev O, Cizmecioglu O, Settele F, Kempf T, Hoffmann I.(2010) Cdc25 phosphatases 450 451 are required for timely assembly of CDK1-cyclin B at the G2/M transition. Journal of Biological 452 Chemistry, 285(22):16978-90. doi: 10.1074/jbc.M109.096552.
- [45] Goebel EJ, Corpina RA, Hinck CS, Czepnik M, Castonguay R, Grenha R, Boisvert A, 453 Miklossy G, Fullerton PT, Matzuk MM, Idone VJ, Economides AN, Kumar R, Hinck AP, 454
- Thompson TB.(2019) Structural characterization of an activin class ternary receptor complex 455
- reveals a third paradigm for receptor specificity. Proceedings of the National Academy of 456 457 Sciences of the United states of America, 116(31):15505-15513. doi: 10.1073/pnas.1906253116.
- 458 [46] Jeon J, Lee H, Jeon MS, Kim SJ, Choi C, Kim KW, Yang DJ, Lee S, Bae YS, Choi WI, Jung
- J, Evun SI, Yang S.(2023) Blockade of Activin Receptor IIB Protects Arthritis Pathogenesis by 459
- 460 Non-Amplification of Activin A-ACVR2B-NOX4 Axis Pathway. Advanced Science (Weinheim
- Baden-Wurrtemberg, Germany), 10(14):e2205161. doi: 10.1002/advs.202205161. 461

462



Figure 1.Flowchart of the design of this study.

## Figure1



Figure 2.Mendelian randomisation results of druggable genes with CP.

# Figure2



Figure 3. Results of MR studies of the full phenotypic range of MMP25.

## Figure3